Lumos Pharma Statistics
Total Valuation
Lumos Pharma has a market cap or net worth of $35.50 million. The enterprise value is $19.80 million.
Important Dates
The next estimated earnings date is Friday, November 8, 2024, after market close.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Lumos Pharma has 8.12 million shares outstanding. The number of shares has decreased by -2.41% in one year.
Shares Outstanding | 8.12M |
Shares Change (YoY) | -2.41% |
Shares Change (QoQ) | +0.09% |
Owned by Insiders (%) | 14.80% |
Owned by Institutions (%) | 29.75% |
Float | 5.32M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 24.24 |
Forward PS | n/a |
PB Ratio | 3.52 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 13.33 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.23, with a Debt / Equity ratio of 0.04.
Current Ratio | 4.23 |
Quick Ratio | 3.44 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -132.56% and return on invested capital (ROIC) is -85.92%.
Return on Equity (ROE) | -132.56% |
Return on Assets (ROA) | -60.50% |
Return on Capital (ROIC) | -85.92% |
Revenue Per Employee | $45,030 |
Profits Per Employee | -$1.08M |
Employee Count | 33 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.92% in the last 52 weeks. The beta is 0.36, so Lumos Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.36 |
52-Week Price Change | +15.92% |
50-Day Moving Average | 3.84 |
200-Day Moving Average | 2.88 |
Relative Strength Index (RSI) | 61.51 |
Average Volume (20 Days) | 97,207 |
Short Selling Information
The latest short interest is 285,411, so 3.51% of the outstanding shares have been sold short.
Short Interest | 285,411 |
Short Previous Month | 300,199 |
Short % of Shares Out | 3.51% |
Short % of Float | 5.37% |
Short Ratio (days to cover) | 10.16 |
Income Statement
In the last 12 months, Lumos Pharma had revenue of $1.49 million and -$35.75 million in losses. Loss per share was -$4.42.
Revenue | 1.49M |
Gross Profit | 1.49M |
Operating Income | -37.62M |
Pretax Income | -35.75M |
Net Income | -35.75M |
EBITDA | -37.59M |
EBIT | -37.62M |
Loss Per Share | -$4.42 |
Full Income Statement Balance Sheet
The company has $16.80 million in cash and $449,000 in debt, giving a net cash position of $16.35 million or $2.01 per share.
Cash & Cash Equivalents | 16.80M |
Total Debt | 449,000 |
Net Cash | 16.35M |
Net Cash Per Share | $2.01 |
Equity (Book Value) | 10.28M |
Book Value Per Share | 1.26 |
Working Capital | 15.96M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -34.49M |
Capital Expenditures | n/a |
Free Cash Flow | -34.49M |
FCF Per Share | -$4.25 |
Full Cash Flow Statement Margins
Gross Margin | 100.00% |
Operating Margin | -2,531.70% |
Pretax Margin | -2,405.72% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -2,320.79% |
Dividends & Yields
Lumos Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 2.41% |
Shareholder Yield | 2.41% |
Earnings Yield | -98.89% |
FCF Yield | -95.39% |
Analyst Forecast
The average price target for Lumos Pharma is $9.38, which is 114.65% higher than the current price. The consensus rating is "Buy".
Price Target | $9.38 |
Price Target Difference | 114.65% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | 142.21% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Lumos Pharma has an Altman Z-Score of -15.31 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -15.31 |
Piotroski F-Score | 2 |